Welcome to our dedicated page for Greenbank Capita news (Ticker: GRNBF), a resource for investors and traders seeking the latest updates and insights on Greenbank Capita stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Greenbank Capita's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Greenbank Capita's position in the market.
GreenBank Capital (OTC: GRNBF) announced a multi-phase agreement through its subsidiary, Substantia Group, to facilitate a landmark carbon-neutral development in the UK. This project seeks to turn a prominent town into a city, aligning with the UK's 'Global Britain' objectives and supporting the Thames Estuary Growth Board's ambitious plan for the region. The project includes residential units, a university, and retail spaces, with an estimated Gross Development Value exceeding £800 million. GreenBank's investment will be up to £500,000 in phase one and £7 million secured loan in phase two.
Summary not available.
GreenBank Capital Inc. (OTC:GRNBF) announced that CodiKoat's antiviral coating effectively neutralizes over 90% of the Covid-19 virus within 2 seconds and over 99% within 10 seconds, as verified by independent lab tests at University College London. The technology is currently being trialed at the Royal Opera House, with plans for expanded installation due to positive initial feedback. This innovative product aims to reduce hospital-acquired infections significantly and has potential applications across various surfaces, including smartphones and hospital environments.
GreenBank Capital has announced an agreement to acquire a 15% stake in CodiKoat, a UK firm that has developed a patent-pending product capable of destroying COVID-19 and various viruses on contact. The deal involves an initial payment of £540,000 (C$930,000) for 5% of CodiKoat's shares, with a 12-month option to acquire an additional 10%. CodiKoat's technology promises permanent virus inactivation through a unique coating process. This partnership aims to enhance public health safety and position CodiKoat for potential future growth in the market.
GreenBank Capital announces a £2 million investment from UKTV Ventures in Beelivery, where GreenBank aims to acquire up to 25% of Beelivery's capital. This funding will accelerate Beelivery's strategy to gain 450,000 customers over two years. Beelivery boasts a profitable model with average delivery times of 46 minutes and over 20,000 drivers, positioning it uniquely in the online grocery market. GreenBank projects Beelivery's orders could exceed £370 million in fiscal year 2023, leveraging its competitive advantages over loss-making peers.
GreenBank Capital (OTC PINK:GRNBF) announced that its portfolio company, Staminier, has successfully raised £10m ($17.2m) to complete the acquisition of The Substantia Group. This acquisition includes a development pipeline valued at £800m ($1.4bn), aiming to enhance Staminier's growth potential. Substantia provides expertise in planning/zoning, crucial for Staminier’s land options at Gatwick Airport, valued at £39m ($67m). The funding was obtained via a convertible loan, with GreenBank holding a 19% stake in Staminier, seeking to acquire the remaining shares soon.
GreenBank Capital has acquired a 25% stake in Flex Capital, a fintech company focused on enhancing donation transparency through its upcoming Eflex app. This app aims to elevate donor satisfaction by allowing individuals to track their contributions' impact on various causes. Flex anticipates processing transactions exceeding C$1 billion annually and will generate revenue via transaction fees. GreenBank's investment positions it as a board member and lead advisor for Flex's future financing.
GreenBank Capital has successfully facilitated Pharmakure in raising £4m (C$7m) to acquire CynapseDx Ltd, enhancing its Alzheimer's treatment capabilities. The acquisition integrates CDX's innovative biomarker technology with Pharmakure’s repurposed drugs, aimed at expediting clinical trials. Following a successful listing on the Canadian Securities Exchange, Pharmakure may receive further funding of up to CA$26m for its Phase II trials. Successful trials could significantly elevate Pharmakure’s market value, creating opportunities for lucrative partnerships.
GreenBank Capital has successfully completed a non-brokered private placement, closing on March 31, 2021, raising $4,458,859 by issuing 9,908,573 units at $0.45 per unit. Each unit comprises one common share and half a warrant, enabling the purchase of additional shares at $0.50 each over 36 months. The financing aims to support further acquisitions and working capital. Notably, the placement included participation from company insiders, deemed a 'related party transaction' but exempt from minority approval due to valuation thresholds.
GreenBank Capital invites investors to its real-time presentation at the Emerging Growth Conference on March 31, 2021. CEO David Lonsdale will discuss recent investments, a successful private placement, and future plans during a 30-minute session starting at 9:30 AM Eastern Time. The event allows attendees to interact and ask questions directly. Registration is available online, and an archived webcast will be accessible afterward. GreenBank is focused on investing in undervalued growth companies, promoting capital appreciation.